Pharma BD Deal Intelligence

GSK plc / Stiefel Laboratories

2009 · Acquisition/Merger · $3.6B · Complete

GSK's $3.6B all-cash acquisition of Stiefel made it the world's largest dermatology drug company overnight, and the deal ultimately achieved its stated strategic rationale. Financial return and pipeline outcome lagged strategic fit, reflecting a solid but unspectacular integration rather than a breakout win.

The Street Said

Strongly positive — critic reaction at announcement

History Says

Largely worked — most objectives met

CALLED IT — OFF BY 11

GSK / Stiefel Laboratories: Achieved Stated Rationale (Score: 68/100)

Full analysis, sources & comparables →

GSK acquired Stiefel Laboratories for $3.6B, world's largest independent dermatology drug company.

Did it work? Outcome assessment

GSK / Stiefel Laboratories: Achieved Stated Rationale (Score: 68/100)

Strategic verdict

Achieved Stated Rationale

Assessment window: 15yr post-close.

Key facts

Announced Apr 20, 2009
Closed Jul 22, 2009
Deal value $3.6B
Deal type Acquisition/Merger
Therapeutic area Dermatology

Disease & market context

Dermatology (Prescription)

50M US cases/yr · $10.0B Global Prescription Dermatology Market (2009) · $1.5B Combined GSK + Stiefel Derm Revenue (2008)

Disease Overview

Stiefel was the world's largest independent dermatology company with ~$900M in 2008 sales. GSK's $3.6B acquisition created a combined $1.5B franchise with 8% global market share. Key products: Duac (acne), Soriatane (psoriasis), Olux (dermatitis), plus 15+ pipeline projects.

Competitive Landscape

The dermatology market in 2009 was fragmented. J&J, Galderma, and Allergan were key competitors. The market was shifting toward biologics for psoriasis. GSK's dermatology strategy was later deprioritized.

Deal timeline

Jul 22, 2009
Deal Closes for $3.6B
GSK plc closes acquisition/merger of Stiefel Laboratories for $3.6B, establishing strategic position and initiating integration.
Jul 22, 2009
GSK / Stiefel Laboratories: Achieved Stated Rationale (Score: 68/100)
Strategic Fit: 75/100 | Financial Return: 68/100 | Pipeline Outcome: 60/100 | Integration: 72/100 | Deal Difficulty: 45/100. Achieved Stated Rationale overall outcome.

Related deals — scored

Deal	Year	Value	Outcome
GSK plc / Stiefel Laboratories (this deal)	2009	$3.6B	64
GSK plc / SmithKline Beecham	2000	$12.0B	79
GSK plc / Pfizer Inc.	2018	$0.0M	77
GSK plc / Novartis AG	2014	$16.0B	76
GSK plc / Hansoh Pharmaceutical Group Co. Ltd.	2023	$1.7B	74
GSK plc / Nuvalent, Inc.	2026	$10.6B	70
GSK plc / Sierra Oncology Inc.	2022	$1.9B	70

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2009 deals · GSK plc deals · Dermatology deals